Apoptosis deregulation and the development of cancer multi-drug resistance
Simple Summary Despite recent therapeutic advances against cancer, many patients do not
respond well or respond poorly, to treatment and develop resistance to more than one anti …
respond well or respond poorly, to treatment and develop resistance to more than one anti …
Regulation and function of the PD-L1 checkpoint
Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
Intratumoral copper modulates PD-L1 expression and influences tumor immune evasion
Therapeutic checkpoint antibodies blocking programmed death receptor 1/programmed
death ligand 1 (PD-L1) signaling have radically improved clinical outcomes in cancer …
death ligand 1 (PD-L1) signaling have radically improved clinical outcomes in cancer …
Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond
L Ai, A Xu, J Xu - Regulation of Cancer Immune Checkpoints: Molecular …, 2020 - Springer
Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in a wide
variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells …
variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells …
[HTML][HTML] TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
Background Osimertinib is a potent, third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study …
(EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study …
Antitumour immunity regulated by aberrant ERBB family signalling
S Kumagai, S Koyama, H Nishikawa - Nature Reviews Cancer, 2021 - nature.com
Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …
Emerging role of tumor cell plasticity in modifying therapeutic response
Resistance to cancer therapy is a major barrier to cancer management. Conventional views
have proposed that acquisition of resistance may result from genetic mutations. However …
have proposed that acquisition of resistance may result from genetic mutations. However …
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
ZY Dong, WZ Zhong, XC Zhang, J Su, Z Xie, SY Liu… - Clinical cancer …, 2017 - AACR
Purpose: Although clinical studies have shown promise for targeting programmed cell death
protein-1 (PD-1) and ligand (PD-L1) signaling in non–small cell lung cancer (NSCLC), the …
protein-1 (PD-1) and ligand (PD-L1) signaling in non–small cell lung cancer (NSCLC), the …
[HTML][HTML] A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC
A Lisberg, A Cummings, JW Goldman… - Journal of Thoracic …, 2018 - Elsevier
Background Despite the significant antitumor activity of pembrolizumab in NSCLC, clinical
benefit has been less frequently observed in patients whose tumors harbor EGFR mutations …
benefit has been less frequently observed in patients whose tumors harbor EGFR mutations …
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective …
Purpose: PD-1 inhibitors are established agents in the management of non–small cell lung
cancer (NSCLC); however, only a subset of patients derives clinical benefit. To determine …
cancer (NSCLC); however, only a subset of patients derives clinical benefit. To determine …